We believe that our lead product candidates have demonstrated, in clinical trials and/or in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.
We have clinical development programs in:


Theravance Key Programs   

KEY PROGRAMS DEVELOPMENT STATUS
BACTERIAL INFECTIONS:  
Telavancin: cSSSI NDA Filed
Telavancin: HAP NDA Filed
RESPIRATORY:  
Horizon Phase 2 POC
MABA Phase 2 POC

In the table above:
  • Development Status indicates the most advanced stage of development that has been completed or is in process.
  • Phase 2 POC indicates that clinical safety testing and preliminary efficacy testing in a patient population has been successfully completed in at least one Phase 2 clinical study.
  • NDA Submitted indicates that a new drug application has been submitted to the FDA, but not yet accepted for filing by the FDA.
  • NDA Filed indicates that a new drug application has been submitted to and accepted for filing by the FDA.
©2009 Theravance, Inc. Theravance, the Theravance logo and Medicines That Make a Difference are registered trademarks of Theravance, Inc. Trademarks, trade names or service marks of other companies appearing on this website are the property of their respective owners. All rights reserved.

Terms of Use     Website Admin Contact     Theravance Contact     Site Map